What question did this study set out to answer?

This study aims to evaluate the effectiveness and safety of the ustekinumab biosimilar in clinical practice for patients with IBD.

P0611Effectiveness and safety of ustekinumab biosimilar for Inflammatory Bowel Disease in real-world clinical practice: 1-year outcomes.

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the effectiveness and safety of the ustekinumab biosimilar in clinical practice for patients with IBD.
Observational, prospective, single-center study
Included patients with inflammatory bowel disease
Treated with ustekinumab biosimilar (Uzpruvo®) as maintenance therapy
Clinical and biochemical remission assessed by standard measures
79 patients were analyzed after transitioning from originator ustekinumab to biosimilar
Significant improvement in median HBI for Crohn's disease (4 to 3) post-switch (p = 0.006)
Median partial Mayo score remained stable for ulcerative colitis (3 to 2) after transition (p > 0.999)
No significant changes in fecal calprotectin or C-reactive protein levels
No serious adverse events reported during 12-month follow-up

No takes yet. Share an insight, caveat, or question.

Observational study evaluates ustekinumab biosimilar effectiveness in IBD, suggesting it as a safe alternative.

Lucena et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark